Mighty Therapeutics, together with its wholly owned operating subsidiary, Stealth BioTherapeutics Inc., is advancing novel therapies for people living with diseases involving mitochondrial dysfunction.

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity.

Clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer and other immune-mediated conditions.

Clinical-stage drug development company focused on developing novel targeted therapies for Alzheimer's disease.

Clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders.

A clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia.

Clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

Clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

Clinical-stage drug development company pioneering precision psychiatry by developing targeted medicines to help patients get better faster.

Clinical-stage precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates.

Clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders.

Clinical-stage immunology focused biopharmaceutical company developing therapies for atopic dermatitis and asthma.

Clinical-stage drug development company pioneering transformative medicines to treat inflammatory and fibrotic diseases by targeting the endocannabinoid system.

Clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers.

Clinical-stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects

Clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization.

Clinical-stage biopharmaceutical company leveraging a proprietary microRNA-based target discovery platform to develop first-in-class small molecule and antibody cancer therapeutics.

Clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases.

Clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics called engineered toxin bodies (ETBs).

Clinical-stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies for cancer.

Clinical stage biotechnology company developing therapeutics targeting stress support pathways.

Clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment.

Dedicated to creating life-changing T Cell therapies for patients by unleashing the untapped potential of the human immune system.

Commercial-stage biopharmaceutical company developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology.